Quantbot Technologies LP Makes New Investment in Pfizer Inc. $PFE

Key Points

• Quantbot Technologies LP acquired 133,304 Pfizer shares during the second quarter, valued at approximately $3.21 million. Hedge funds and other institutional investors collectively own 68.36% of Pfizer.
• Analysts maintain a broadly cautious outlook, with Pfizer carrying a consensus “Hold” rating and an average price target of $28.28. Shares recently opened at $28.00, near their 52-week high of $28.75.
• Pfizer exceeded quarterly earnings expectations, reporting $0.77 in adjusted EPS and $15.03 billion in revenue, while declaring a quarterly dividend of $0.43 per share, equivalent to a 6.1% annualized yield.

Quantbot Technologies LP acquired a new position in Pfizer Inc. (NYSE:PFE - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 133,304 shares of the biopharmaceutical company's stock, valued at approximately $3,210,000.

Other hedge funds have also made changes to their positions in the company. Godfrey Financial Associates Inc. purchased a new stake in Pfizer during the 4th quarter worth $26,000. Keb Asset Management LLC purchased a new position in Pfizer in the second quarter valued at about $26,000. HFM Investment Advisors LLC raised its position in Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 427 shares during the period. Evolution Wealth Management Inc. lifted its stake in shares of Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 566 shares in the last quarter. Finally, Abound Financial LLC acquired a new position in shares of Pfizer during the fourth quarter worth about $31,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on PFE. Weiss Ratings lowered Pfizer from a "hold (c)" rating to a "hold (c-)" rating in a research note on Monday, August 17th. JPMorgan Chase & Co. reduced their price target on Pfizer from $30.00 to $28.00 and set a "neutral" rating on the stock in a research report on Wednesday, July 8th. Wolfe Research restated an "underperform" rating and issued a $26.00 price target on shares of Pfizer in a report on Thursday, May 14th. Guggenheim lowered their price objective on shares of Pfizer from $35.00 to $31.00 and set a "buy" rating for the company in a research report on Friday, August 7th. Finally, Citigroup boosted their target price on shares of Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $28.28.

Pfizer Stock Down 0.2%

Shares of Pfizer stock opened at $28.00 on Monday. Pfizer Inc. has a 1-year low of $23.58 and a 1-year high of $28.75. The company has a market capitalization of $159.59 billion, a PE ratio of 36.84 and a beta of 0.34. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The business has a 50-day moving average of $25.30 and a 200-day moving average of $26.25.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.68 by $0.09. The business had revenue of $15.03 billion for the quarter, compared to analysts' expectations of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The company's revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.1%. Pfizer's dividend payout ratio (DPR) is presently 226.32%.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer completed a Phase 1/2 study of PF-07868489, an experimental treatment for pulmonary arterial hypertension. The milestone supports early-stage pipeline progress, though additional clinical testing will be needed before any potential commercialization. Pfizer’s PF-07868489 PAH Study Reaches Completion
• Positive Sentiment: Several additional clinical updates highlighted progress across Pfizer’s development portfolio: completion of a Phase 1 atirmociclib study, completion of a drug-interaction study for PF-07248144, and a new Phase 1 liver study for atirmociclib. These milestones may reinforce confidence in Pfizer’s ability to replenish revenue as older products face competition. Atirmociclib Study Update PF-07248144 Study Update
• Positive Sentiment: Pfizer is also expanding real-world evidence efforts for prostate cancer therapies, Ibrance in advanced breast cancer, and a migraine treatment study in India. These studies could support broader use and strengthen commercial evidence for existing medicines. Pfizer Real-World Prostate Cancer Study
• Positive Sentiment: Investor-oriented coverage remains constructive, citing Pfizer’s roughly 19% year-to-date gain, attractive dividend yield, and reported hedge-fund buying. The stock’s move toward its 52-week high suggests improving sentiment. Hedge Funds Buying Pfizer
• Neutral Sentiment: Unusually large options activity may increase short-term trading interest, but it does not establish a clear fundamental direction for PFE. Pfizer Options Trading
• Negative Sentiment: Coverage of settlements involving thousands of Depo-Provera lawsuits raises concerns about potential legal costs and ongoing liability. Analysts also continue to weigh whether new drugs and acquisitions can offset revenue losses from expiring patents. Pfizer Legal Claims

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source